Yatomi Masakiyo, Takazawa Tomonori, Yanagisawa Kunio, Kanamoto Masafumi, Matsui Yusuke, Tsukagoshi Hiroyuki, Saruki Nobuhiro, Saito Shigeru, Tokue Yutaka, Maeno Toshitaka
Department of Allergy and Respiratory Medicine, Integrative Center of Internal Medicine, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, Gunma, Japan 371-8511.
Intensive Care Unit, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, Gunma, Japan 371-8511.
Case Rep Infect Dis. 2020 Sep 5;2020:8814249. doi: 10.1155/2020/8814249. eCollection 2020.
Although a variety of existing drugs are being tested for patients with coronavirus disease 2019 (COVID-19), no efficacious treatment has been found so far, particularly for severe cases. We report successful recovery in an elderly patient with severe pneumonia requiring mechanical ventilation and extracorporeal membrane oxygenation (ECMO). Despite administration of multiple antiviral drugs, including lopinavir/ritonavir, chloroquine, and favipiravir, the patient's condition did not improve. However, after administration of another antiviral drug, remdesivir, we were able to terminate invasive interventions, including ECMO, and subsequently obtained negative polymerase chain reaction results. Although further validation is needed, remdesivir might be effective in treating COVID-19.
尽管目前正在对多种现有药物进行2019冠状病毒病(COVID-19)患者的试验,但迄今为止尚未发现有效的治疗方法,尤其是对重症病例。我们报告了一名患有严重肺炎、需要机械通气和体外膜肺氧合(ECMO)的老年患者成功康复的病例。尽管使用了多种抗病毒药物,包括洛匹那韦/利托那韦、氯喹和法匹拉韦,但患者的病情并未改善。然而,在使用另一种抗病毒药物瑞德西韦后,我们得以终止包括ECMO在内的侵入性干预措施,随后获得了聚合酶链反应阴性结果。尽管还需要进一步验证,但瑞德西韦可能对治疗COVID-19有效。